Tuesday, January 31, 2023
Biosynex SA and Chembio Diagnostics announced that they have entered into a definitive merger agreement under which Biosynex, a subsidiary, will acquire Chembio for $0.45 per share.
This acquisition significantly advances the mission to develop, manufacture and market rapid diagnostics for screening, diagnosis and prevention to facilitate patient care and monitor health.
The acquisition combines two leading rapid diagnostic test companies. Chembio’s portfolio of diagnostic solutions and technology platforms complements the existing test portfolio. DPP, SURE CHECK and STAT-PAK are clinically validated with accurate results, ease-of-use, and U.S. FDA and global regulatory approvals including CE marked and WHO prequalified products provide transformative commercial opportunities which represents a meaningful growth drivers over the near and long-term.
The alliance between the two companies provides healthcare professionals and individuals with innovative diagnostic solutions that accelerate care.
